18
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Untersuchungen mit dem computergesteuerten Perimeter Peritest über die Wirkung des Cosaldons A + E auf glaukomatöse Gesichtsfelddefekte

      research-article
      Ophthalmologica
      S. Karger AG
      Glaucoma, Computerized perimeter, Vasoactive treatment, Visual field defects

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Investigations on 114 glaucoma patients with the computerized perimeter ‘Peritest’ showed that treatment with Cosaldon A + E resulted in a decrease or elimination of visual field defects. Favourable results were also obtained with statistical significance for severe visual field defects of defect class≥2.0 logU. Freatment time was generally 4–5 months. During the first 6–10 weeks of treatment strong fluctuations were observed regarding individual sensitivity of light perception as well as number of defect positions.

          Related collections

          Author and article information

          Journal
          OPH
          Ophthalmologica
          10.1159/issn.0030-3755
          Ophthalmologica
          S. Karger AG
          0030-3755
          1423-0267
          1985
          1985
          31 March 2010
          : 191
          : 4
          : 238-249
          Affiliations
          Lübeck, BRD
          Article
          309596 Ophthalmologica 1985;191:238–249
          10.1159/000309596
          4088612
          29bed89b-e843-4821-b83a-5a2f232a4f03
          © 1985 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 05 August 1985
          : 17 August 1985
          Page count
          Pages: 12
          Categories
          Original Paper

          Vision sciences,Ophthalmology & Optometry,Pathology
          Glaucoma,Vasoactive treatment,Visual field defects,Computerized perimeter

          Comments

          Comment on this article